What is NexCure?
NexCure operates at the intersection of biotechnology and healthcare infrastructure, specializing in the delivery of clinically intensive therapeutics within community and outpatient settings. The company addresses the systemic inefficiencies of traditional oncology care by redesigning the delivery, monitoring, and scaling of advanced treatments. Its platform leverages AI-powered patient selection and remote monitoring to maintain high safety standards while reducing the burden on centralized hospital systems. By translating complex clinical protocols into scalable, community-based models, NexCure is effectively democratizing access to life-saving therapies and optimizing the patient journey from diagnosis to survivorship.
How much funding has NexCure raised?
NexCure has raised a total of $19M across 1 funding round:
Series A
$19M
Series A (2026): $19M with participation from Cencora, Oncology Ventures, and RA Capital Management
Key Investors in NexCure
Cencora
Cencora is a global pharmaceutical solutions company that connects manufacturers, providers, and healthcare organizations to improve access to therapies and enhance operational efficiency across the supply chain.
Oncology Ventures
Oncology Ventures is a specialized investment firm focused on healthcare data and technologies that address significant challenges in cancer care, including AI-powered treatment optimization and patient navigation.
RA Capital Management
RA Capital Management is a multi-stage investment manager that utilizes evidence-based strategies and its internal TechAtlas think tank to support innovation in healthcare, life sciences, and medical diagnostics.
What's next for NexCure?
With the recent influx of capital, NexCure is poised to transition from its current development phase into a period of rapid operational expansion. The strategic focus will likely center on enhancing its AI-driven patient selection algorithms and expanding its network of community-based clinics to accommodate a broader range of advanced therapeutics. As the company scales, it will continue to refine its standardized clinical protocols, aiming to set a new benchmark for outpatient oncology care. Investors are closely watching how NexCure utilizes this financing to solidify its market position, particularly as it seeks to integrate more deeply with existing pharmaceutical supply chains and healthcare provider networks to ensure seamless treatment delivery at scale.
See full NexCure company page
